Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Finally, a few studies in mice have found that the medications can reduce the buildup of the protein tau in the brain, which is a key contributor to Alzheimer’s disease. Scaling back tau buildup could ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Ozempic can cause bone density loss and I didn't think that would happen to me because I was only on it for a year. But I ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications. Experts break down the findings.

Katharine Lang reports Glucagon-like peptide-1 (GLP-1) receptor agonist drugs such as liraglutide (Saxenda) and semaglutide (Ozempic, Wegovy) are being hailed as game changers in treating adult ...